Ativan (lorazepam) is typically prescribed for treating anxiety.
Less often, it is used to help reduce nausea and vomiting due tochemotherapy.
Use of Ativan During Chemotherapy
The most common side effect of chemotherapy is nausea and vomiting.
Westend61 / Getty Images
There are many treatments that can help reduce this side effect.
During and following chemotherapy, some people value the mild drowsiness this medication can cause.
While Ativan can be effective, it should not be taken alone as an anti-nausea drug.
Side Effects
You may experience fatigue, dizziness, and weakness while taking Ativan.
If the side effects become bothersome, other anti-nausea medications can be prescribed.
Before stopping or changing the dosage of Ativan, speak with your healthcare provider.
It can also be administered intravenously or by injection, which is helpful if you have severe vomiting.
How Long Does Ativan Last?
The peak concentration in plasma happens about two hours after administration, meaning its effects are strongest then.
What if It Doesn’t Work?
Other Pharmacological Agents:
However, nausea and vomiting can continue beyond five days in many people.
Other drugs, includingbenzodiazepinesandcannabinoids, may offer additional benefits during this time.
Most people require preventative measures, as well as medications.
Trying to tough it out is not advised.
Frequently Asked Questions
It can be, yes.
It is a benzodiazepine, and these drugs can be habit-forming.
If you have a personal or family history of addiction or prescription abuse, talk with your doctor.
Always use the drug exactly as prescribed.
Yes, it typically does.
This drug, especially the generic version, is inexpensive.
ChemoExperts.Lorazepam (Ativan) is a Supportive Care Therapy to prevent or treat Nausea and Vomiting.
Hesketh PJ, Kris MG, Basch E, et al.Antiemetics: ASCO guideline update.J Clin Oncol.
2017;8(3):112115. doi:10.4103/jpp.JPP_54_17
NHS.Lorazepam.
U.S. Food and Drug Administration.Ativan (lorazepam) label.
2022;15(1):100.
2017;21(2):162167. doi:10.5114/wo.2017.66896
